Skip to main content

Table 2 Chemotherapy related toxicities according to CTCAE (Grade I/II) comparing cycles of mSTF (n = 56) with cycles of NC (n = 62)

From: Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study

 NCmSTFPE ± SD*95% CIP-Value
Infection2 (3.4%)4 (7.3%)0.07 ± 0.040.01–0.150.097
Fatigue22 (37.9%)25 (45.5%)-0.01 ± 0.09− 0.20 – 0.170.882
Insomnia2 (3.4%)4 (7.3%)0.03 ± 0.04− 0.05 – 0.110.505
Headachesa2 (5.7%)0−0.03 ± 0.06− 0.14 – 0.090.649
Dizzinessa3 (8.6%)2 (7.1%)−0.10 ± 0.07−0.25 – 0.050.187
Depression2 (3.4%)2 (3.6%)− 0.02 ± 0.04− 0.10 – 0.060.560
Nausea22 (37.9%)16 (29.1%)− 0.01 ± 0.10−0.21 – 0.180.895
Vomiting02 (3.6%)0.02 ± 0.03−0.03 – 0.080.413
Diarrhea2 (3.4%)2 (3.6%)−0.01 ± 0.04−0.09 – 0.070.877
Obstipationb5 (8.8%)4 (7.3%)−0.02 ± 0.06−0.13 – 0.090.688
Stomach painsa1 (2.9%)0−0.02 ± 0.04−0.10 – 0.070.695
Reduced appetitea7 (20.0%)2 (7.1%)−0.16 ± 0.11−0.39 – 0.060.150
Hungerc2 (5.6%)0−0.03 ± 0.06−0.15 – 0.090.606
Stomatitis15 (25.9%)3 (5.5%)−0.16 ± 0.06−0.28 – (− 0.03)0.013
Esophagitis2 (3.4%)2 (3.6%)0.01 ± 0.04− 0.08 – 0.090.892
Neuroses8 (13.8%)10 (18.2%)0.07 ± 0.07−0.06 – 0.200.280
Arthralgia1 (1.7%)2 (3.6%)0.02 ± 0.03−0.05 – 0.090.614
Pain11 (19%)3 (5.5%)− 0.11 ± 0.06−0.23 – 0.010.075
Dyspnea02 (3.6%)0.03 ± 0.02− 0.01 – 0.070.098
Oedemas01 (1.8%)0.0 ± 0.02−0.04 – 0.040.840
  1. Values are shown as mean ± SD. Due to missing data, we included data of 58 cycles of NC and 55 cycles of mSTF in this analysis.*PE ± SD represents the difference for CTCAE points between cycles of NC and those of mSTF. All side effects were scored according to CTCAE v.4.0. Each side effect was scored once per patient during each chemotherapy cycle. a n = 63; b n = 112; c n = 64